BR112014024968A2 - sistema e método para liberação multifásica de fatores de crescimento - Google Patents
sistema e método para liberação multifásica de fatores de crescimentoInfo
- Publication number
- BR112014024968A2 BR112014024968A2 BR112014024968A BR112014024968A BR112014024968A2 BR 112014024968 A2 BR112014024968 A2 BR 112014024968A2 BR 112014024968 A BR112014024968 A BR 112014024968A BR 112014024968 A BR112014024968 A BR 112014024968A BR 112014024968 A2 BR112014024968 A2 BR 112014024968A2
- Authority
- BR
- Brazil
- Prior art keywords
- growth factor
- multiphase
- releasing
- released
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ceramic Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polymers & Plastics (AREA)
- Materials For Medical Uses (AREA)
Abstract
resumo patente de invenção: "sistema e método para liberação multifásica de fatores de crescimento". um sistema para entrega multifásica de pelo menos um fator de crescimento em um local de tratamento compreende um veículo de entrega para liberar pelo menos um fator de crescimento em um perfil de liberação inicial e um carreador para liberar pelo menos um fator de crescimento em um perfil de liberação sustentada. o perfil de liberação inicial libera pelo menos um fator de crescimento no período de horas a dias, cujo fator de crescimento é liberado em grande quantidade inicialmente, com o restante sendo liberado em quantidades progressivamente mais baixas. o perfil de liberação sustentada libera pelo menos um fator de crescimento no período de dias a semanas, em que o fator de crescimento é liberado por uma quantidade geralmente constante durante tal período. o sistema é particularmente ajustado para aplicações em bioimplantes. a invenção também compreende métodos e kits para entrega multifásica de pelo menos um fator de crescimento. a invenção também compreende sulfato de cálcio como veículo para liberar pelo menos um fator de crescimento em sistemas únicos e multifásicos para entregar pelo menos um fator de crescimento em um local de tratamento. 22605122v1 1/1 22605122v1
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161474049P | 2011-04-11 | 2011-04-11 | |
PCT/CA2012/050234 WO2012139223A1 (en) | 2011-04-11 | 2012-04-11 | System and method for multiphasic release of growth factors |
CAPCT/CA2012/050234 | 2012-04-11 | ||
PCT/CA2012/050738 WO2013152418A1 (en) | 2012-04-11 | 2012-10-17 | System and method for multiphasic release of growth factors |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014024968A2 true BR112014024968A2 (pt) | 2017-07-11 |
BR112014024968B1 BR112014024968B1 (pt) | 2022-11-29 |
Family
ID=47008753
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013026241A BR112013026241A2 (pt) | 2011-04-11 | 2012-04-11 | sistema e método para liberação multifásica de fatores de crescimento |
BR112014024968-7A BR112014024968B1 (pt) | 2011-04-11 | 2012-10-17 | Sistemas na forma de bioimplantes com mistura de particulado em gel de poloxâmero para liberação multifásica de fatores de crescimento |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013026241A BR112013026241A2 (pt) | 2011-04-11 | 2012-04-11 | sistema e método para liberação multifásica de fatores de crescimento |
Country Status (11)
Country | Link |
---|---|
US (5) | US9675670B2 (pt) |
EP (1) | EP2696852B1 (pt) |
JP (1) | JP6224579B2 (pt) |
CN (1) | CN103596553B (pt) |
AU (2) | AU2012243410B8 (pt) |
BR (2) | BR112013026241A2 (pt) |
CA (1) | CA2833023C (pt) |
DK (1) | DK2836195T3 (pt) |
RU (2) | RU2017134806A (pt) |
WO (1) | WO2012139223A1 (pt) |
ZA (1) | ZA201307453B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014159863A1 (en) * | 2013-03-14 | 2014-10-02 | Genzyme Corporation | Thermo-sensitive bone growth compositions |
US10265437B2 (en) * | 2014-03-14 | 2019-04-23 | The Research Foundation For The State University Of New York | Neurogenic regulation of bone growth and bone degradation |
CN104894069B (zh) * | 2015-05-07 | 2019-07-12 | 中国人民解放军第四军医大学 | 一种光控胰岛素节律性分泌的组织工程装置 |
CN107412859B (zh) * | 2017-04-26 | 2020-07-14 | 温州医科大学附属口腔医院 | 一种双基因时序性缓释的组织工程支架材料的制备方法 |
RU2665155C1 (ru) * | 2018-01-10 | 2018-08-28 | федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации | Способ доставки биологически активных веществ в скаффолд |
CN109568670B (zh) * | 2018-10-24 | 2021-05-07 | 温州医科大学 | 一种子宫内膜损伤修复的水凝胶及其制备方法 |
JP7128902B2 (ja) * | 2018-12-25 | 2022-08-31 | Orthorebirth株式会社 | 複数の電界紡糸繊維からなる綿形状の構造を有する骨再生用材料 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4789732A (en) | 1980-08-04 | 1988-12-06 | Regents Of The University Of California | Bone morphogenetic protein composition |
US4761471A (en) | 1980-08-04 | 1988-08-02 | The Regents Of The University Of California | Bone morphogenetic protein composition |
US4795804A (en) | 1983-08-16 | 1989-01-03 | The Regents Of The University Of California | Bone morphogenetic agents |
US4857456A (en) | 1985-04-30 | 1989-08-15 | The Regents Of The University Of California | Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders |
US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
US4877864A (en) | 1987-03-26 | 1989-10-31 | Genetics Institute, Inc. | Osteoinductive factors |
US5631142A (en) | 1986-07-01 | 1997-05-20 | Genetics Institute, Inc. | Compositions comprising bone morphogenetic protein-2 (BMP-2) |
KR100259827B1 (ko) | 1991-11-04 | 2000-06-15 | 브루스 엠. 에이센, 토마스 제이 데스로저 | 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법 |
US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
GB9415810D0 (en) * | 1994-08-04 | 1994-09-28 | Jerrow Mohammad A Z | Composition |
US6281195B1 (en) * | 1997-02-07 | 2001-08-28 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
DE60017363T2 (de) | 1999-02-02 | 2006-03-02 | Wright Medical Technology Inc., Arlington | Kontrollierte freisetzung eines verbundmaterials |
US6998137B2 (en) | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
US6589549B2 (en) * | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US20070190102A1 (en) | 2000-06-30 | 2007-08-16 | Ping Luo | Method of preparing hydroxyapatite based drug delivery implant for infection and cancer treatment |
US6503109B1 (en) | 2000-07-19 | 2003-01-07 | Marshall D. Duffield | Swivel drive assembly |
US20080233165A1 (en) | 2000-08-07 | 2008-09-25 | Biolok International, Inc. | Time release calcium sulfate and growth factor matrix for bone augmentation |
US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
US7671012B2 (en) * | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
CN1267590C (zh) * | 2004-06-11 | 2006-08-02 | 清华大学 | 一种用于组织修复的生长因子缓释体系的制备方法 |
US7325262B2 (en) | 2005-03-02 | 2008-02-05 | Standard Textile Co., Inc. | Bedding hem with associated interlining |
WO2006122183A2 (en) | 2005-05-10 | 2006-11-16 | Cytophil, Inc. | Injectable hydrogels and methods of making and using same |
US20060257492A1 (en) * | 2005-05-13 | 2006-11-16 | Depuy Products, Inc. | Suspension of calcium phosphate particulates for local delivery of therapeutic agents |
CN1733311A (zh) * | 2005-08-18 | 2006-02-15 | 同济大学 | 一种包裹药物或生长因子的纳米纤维的制备方法 |
US20070248675A1 (en) | 2005-09-08 | 2007-10-25 | Gwangju Institute Of Science And Technology | Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof |
CA2650542C (en) | 2006-04-25 | 2016-09-13 | Teleflex Medical Incorporated | Calcium phosphate polymer composite and method |
US20090264489A1 (en) | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation |
AU2009200540A1 (en) | 2008-07-03 | 2010-01-21 | Induce Biologics Inc. | Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness |
US9492375B2 (en) * | 2008-07-23 | 2016-11-15 | Warsaw Orthopedic, Inc. | Foam carrier for bone grafting |
WO2010017288A1 (en) | 2008-08-05 | 2010-02-11 | The University Of Miami | Composite bone grafts, particulate bone-calcium sulfate constructs, and methods of treating joint injuries |
US20110027331A1 (en) | 2009-07-29 | 2011-02-03 | Warsaw Orthopedic, Inc. | An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation |
-
2012
- 2012-04-11 CA CA2833023A patent/CA2833023C/en active Active
- 2012-04-11 BR BR112013026241A patent/BR112013026241A2/pt not_active IP Right Cessation
- 2012-04-11 RU RU2017134806A patent/RU2017134806A/ru not_active Application Discontinuation
- 2012-04-11 JP JP2014504131A patent/JP6224579B2/ja active Active
- 2012-04-11 RU RU2013150080A patent/RU2633057C2/ru not_active IP Right Cessation
- 2012-04-11 AU AU2012243410A patent/AU2012243410B8/en active Active
- 2012-04-11 EP EP12771478.0A patent/EP2696852B1/en active Active
- 2012-04-11 WO PCT/CA2012/050234 patent/WO2012139223A1/en active Application Filing
- 2012-04-11 CN CN201280017716.1A patent/CN103596553B/zh active Active
- 2012-04-11 US US14/111,518 patent/US9675670B2/en active Active
- 2012-10-17 BR BR112014024968-7A patent/BR112014024968B1/pt active IP Right Grant
- 2012-10-17 DK DK12874355.6T patent/DK2836195T3/da active
-
2013
- 2013-10-07 ZA ZA201307453A patent/ZA201307453B/en unknown
-
2014
- 2014-10-08 US US14/509,840 patent/US9724389B2/en active Active
-
2017
- 2017-02-03 AU AU2017200773A patent/AU2017200773A1/en not_active Abandoned
- 2017-06-07 US US15/616,563 patent/US20170266259A1/en not_active Abandoned
- 2017-08-04 US US15/669,425 patent/US20170340707A1/en not_active Abandoned
-
2018
- 2018-12-04 US US16/209,510 patent/US20190117734A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20140100161A1 (en) | 2014-04-10 |
CN103596553B (zh) | 2019-01-08 |
RU2633057C2 (ru) | 2017-10-11 |
AU2012243410B8 (en) | 2016-11-17 |
BR112014024968B1 (pt) | 2022-11-29 |
US20170340707A1 (en) | 2017-11-30 |
US20190117734A1 (en) | 2019-04-25 |
WO2012139223A1 (en) | 2012-10-18 |
AU2017200773A1 (en) | 2017-03-02 |
BR112013026241A2 (pt) | 2019-09-24 |
JP2014510763A (ja) | 2014-05-01 |
AU2012243410A1 (en) | 2013-05-09 |
AU2012243410A8 (en) | 2016-11-17 |
ZA201307453B (en) | 2019-11-27 |
RU2013150080A (ru) | 2015-05-20 |
JP6224579B2 (ja) | 2017-11-01 |
RU2017134806A (ru) | 2019-02-07 |
CA2833023C (en) | 2020-07-21 |
EP2696852A4 (en) | 2014-09-24 |
CN103596553A (zh) | 2014-02-19 |
US9675670B2 (en) | 2017-06-13 |
EP2696852A1 (en) | 2014-02-19 |
DK2836195T3 (da) | 2021-05-25 |
EP2696852B1 (en) | 2018-06-06 |
US20150196620A1 (en) | 2015-07-16 |
CA2833023A1 (en) | 2012-10-18 |
AU2012243410B2 (en) | 2016-11-03 |
US9724389B2 (en) | 2017-08-08 |
US20170266259A1 (en) | 2017-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014024968A2 (pt) | sistema e método para liberação multifásica de fatores de crescimento | |
MX2022013590A (es) | Metodos y composiciones para el tratamiento de trastorno por deficit de atencion. | |
BR112013031389A2 (pt) | instrumento cirúrgico | |
CL2009000650A1 (es) | Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras | |
ECSP13012966A (es) | Derivados de acido 3-fenilpropionoco ramificados y su uso | |
BR112015029970A2 (pt) | inibidores de cinase | |
BR112014010900A2 (pt) | métodos de preparar sistema de catalisador | |
CL2017001460A1 (es) | Compuestos de acido hidroxámico de isoxazole como inhibidores de lpxc | |
BR112015003806A2 (pt) | implante ósseo | |
MX2015008021A (es) | Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos. | |
BR112017007864A2 (pt) | método e sistema de tratamento de uma formação subterrânea, sistema para realizar um método, composição de peso aumentado, e, método de preparo de uma composição de peso aumentado. | |
MY182222A (en) | Pharmaceutical compositions and methods of use of 4-pregenen- 11?-17-21-triol-3,20-dione derivatives | |
MX349802B (es) | Uso de aril- y hetarilcarboxamidas como endoparasiticidas. | |
BR112013000776A2 (pt) | método e formulação para tratamento de deficiência de ácido siálico | |
MX2013013891A (es) | Sistema y metodo de tratamiento de agua anti-incrustaciones. | |
CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
EP3730614A3 (en) | Modulators of growth hormone receptor | |
CO6571879A2 (es) | Composición de control de fitoenfermedades y su uso | |
BR112013029149A2 (pt) | processo de produção de material inorgânico em partículas | |
BR112013025696A2 (pt) | composição compreendendo cimento portland para utilização em vertebroplastia | |
IN2014DN08829A (pt) | ||
PA8798401A1 (es) | Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida | |
CL2013000335A1 (es) | Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension. | |
PE20142436A1 (es) | Metodo para la estabilizacion de emplasto beta-hemihidratado | |
CL2012003645A1 (es) | Composicion farmaceutica de liberacion sostenida que comprende un compuesto derivado de metastina y un polimero de acido lactico; metodo de produccion; su uso para el tratamiento o prevencion del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/10/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |